Currently, there is a new pharmacological modality for chronic constipation available in Indonesia: Elobixibat. Elobixibat is a bile acid transporter inhibitor that works by inhibiting the reabsorption of bile salts in enterocytes in the ileum, so that the residual bile acids can increase water secretion and facilitate bowel movements. This medication also has the advantage of improving dyslipidemia by inhibiting fat absorption.

This new therapy is expected to be an alternative treatment for chronic constipation cases. This has prompted the Indonesian Gastroenterology Association (PB PGI) to review Elobixibat through the Addendum to the National Consensus on the Management of Constipation in Indonesia 2023. This consensus addendum refers to the latest similar guidelines and is based on evidence-based medicine, so it can be used as a reference for doctors in Indonesia in managing chronic constipation in daily practice.

The Addendum to the National Consensus on the Management of Constipation in Indonesia 2023 was conducted on December 17, 2023, via Zoom meeting. The event was attended by 46 panelists, including advisors and members of the Indonesian Gastroenterology Association (PB PGI), as well as the heads of the PPHI-PEGI-PGI branches throughout Indonesia/branch representatives.

We hope this addendum can serve as a guide for doctors, including general practitioners, internal medicine specialists, and gastroenterology consultants, in improving patient care.